Prof Anders Behndig (Umeå University Hospital, Umeå, Sweden) discusses the findings from his ongoing study comparing the efficacy, safety and healing phase of two different Customized Remodeled Vision (CuRV) crosslinking protocols for keratoconus.
Questions
- Could you give us a brief overview of customized remodeled vision (CuRV) crosslinking protocols for keratoconus, and their advantages? 00:12-01:25
- What were the aims and designs of the study you presented at ESCRS? 01:25-02:38
- What have been the findings of the study to date? 02:38-04:55
- Which patients are most likely to benefit from the high-oxygen epi-on treatment protocol? 04:55-06:17
- What do you think the future holds for the epi-on treatment? 06:17-06:55
Disclosures: Prof Anders Behndig has no actual or potential conflicts of interest in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sohpie Nickelson.
Filmed in coverage of the ESCRS Winter 2022 meeting
